NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 11/30/2017.
  • Additional Information
    • Alternate Title:
      Neuro-Disease-Program
    • Subject Terms:
      Sweden; United States of America
    • Abstract:
      LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental modelsof genetic mitochondrial disease and that a lead compound has been selected. The lead was selected based on tolerability, plasma stability and organ delivery, specifically to the brain, and will now be taken into further in vivo experimental efficacy studies and preclinical development. [ABSTRACT FROM PUBLISHER]